MARKET

GTBP

GTBP

Gt Biopharma Inc
NASDAQ
2.300
+0.030
+1.32%
Closed 14:57 05/12 EDT
OPEN
2.200
PREV CLOSE
2.270
HIGH
2.325
LOW
2.200
VOLUME
5.05K
TURNOVER
0
52 WEEK HIGH
10.66
52 WEEK LOW
1.720
MARKET CAP
5.83M
P/E (TTM)
-0.3316
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at GTBP last week (0505-0509)?
Weekly Report · 23h ago
GT Biopharma Inc <GTBP.OQ> expected to post a loss of 64 cents a share - Earnings Preview
Reuters · 3d ago
GT Biopharma Appoints Michael Breen as New CEO
TipRanks · 05/05 20:40
GT Biopharma Appoints Michael Breen As CEO For Two-Year Term
Benzinga · 05/05 20:38
GT BIOPHARMA INC - ON APRIL 29, APPOINTS MICHAEL BREEN AS CEO FOR TWO-YEAR TERM - SEC FILING
Reuters · 05/05 20:33
Weekly Report: what happened at GTBP last week (0428-0502)?
Weekly Report · 05/05 12:13
Weekly Report: what happened at GTBP last week (0421-0425)?
Weekly Report · 04/28 12:26
Weekly Report: what happened at GTBP last week (0414-0418)?
Weekly Report · 04/21 12:25
More
About GTBP
More
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Recently
Symbol
Price
%Change

Webull offers GT Biopharma Inc stock information, including NASDAQ: GTBP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GTBP stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading GTBP stock methods without spending real money on the virtual paper trading platform.